Clearwater Capital Advisors, LLC Crispr Therapeutics Ag Transaction History

Clearwater Capital Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	BUY	$38.62 - $72.18 $128,874 - $240,864	3,337 New	3,337 $208,000
Q3 2022 Nov 01, 2022	BUY	$61.1 - $83.78 $197,536 - $270,860	3,233 New	3,233 $211,000
Q1 2022 May 03, 2022	SELL	$53.19 - $79.24 $155,367 - $231,460	-2,921 Closed	0 $0
Q4 2021 Jan 26, 2022	BUY	$70.09 - $111.29 $25,162 - $39,953	359 Added 14.01%	2,921 $221,000
Q3 2021 Nov 03, 2021	BUY	$110.2 - $156.64 $39,231 - $55,763	356 Added 16.14%	2,562 $287,000
Q2 2021 Aug 04, 2021	SELL	$100.84 - $161.89 $504 - $809	-5 Reduced 0.23%	2,206 $357,000
Q1 2021 Apr 21, 2021	BUY	$110.72 - $210.04 $95,551 - $181,264	863 Added 64.02%	2,211 $269,000
Q4 2020 Jan 21, 2021	BUY	$79.67 - $173.23 $107,395 - $233,514	1,348 New	1,348 $206,000

488

57.8M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.21B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Clearwater Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Clearwater Capital Advisors, LLC with notifications on news.